Literature DB >> 18293909

Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor.

Brian E Kane1, Christopher R McCurdy, David M Ferguson.   

Abstract

The structural basis to salvinorin A recognition of the kappa-opioid receptor is evaluated using a combination of site-directed mutagenesis and molecular-modeling techniques. The results show that salvinorin A recognizes a collection of residues in transmembrane II and VII, including Q115, Y119, Y313, I316, and Y320. The mutation of one hydrophobic residue in particular, I316, was found to completely abolish salvinorin A binding. As expected, none of the residues in transmembrane III or VI commonly associated with opiate recognition (such as D138 or E297) appear to be required for ligand binding. On the basis of the results presented here and elsewhere, a binding site model is proposed that aligns salvinorin A vertically within a pocket spanning transmembrane II and VII, with the 2' substituent directed toward the extracellular domains. The model explains the role that hydrophobic contacts play in binding this lipophilic ligand and gives insight into the structural basis to the mu-opioid receptor selectivity of 2'-benzoyl salvinorin (herkinorin).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18293909     DOI: 10.1021/jm701040v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Chemotype-selective modes of action of κ-opioid receptor agonists.

Authors:  Eyal Vardy; Philip D Mosier; Kevin J Frankowski; Huixian Wu; Vsevolod Katritch; Richard B Westkaemper; Jeffrey Aubé; Raymond C Stevens; Bryan L Roth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

2.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

3.  'Carba'-carfentanil (trans isomer): a μ opioid receptor (MOR) partial agonist with a distinct binding mode.

Authors:  Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Jason J Guo; Brian C Wilkes; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-07-29       Impact factor: 3.641

Review 4.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

5.  "Carba"-analogues of fentanyl are opioid receptor agonists.

Authors:  Grazyna Weltrowska; Nga N Chung; Carole Lemieux; Jianxin Guo; Yixin Lu; Brian C Wilkes; Peter W Schiller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

6.  Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.

Authors:  Anthony Lozama; Christopher W Cunningham; Michael J Caspers; Justin T Douglas; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2011-02-21       Impact factor: 4.050

7.  CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.

Authors:  Donna L McGovern; Philip D Mosier; Bryan L Roth; Richard B Westkaemper
Journal:  J Mol Graph Model       Date:  2010-01-04       Impact factor: 2.518

8.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

9.  Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

Authors:  B Simonson; A S Morani; A W M Ewald; L Walker; N Kumar; D Simpson; J H Miller; T E Prisinzano; B M Kivell
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 10.  Progress in structure based drug design for G protein-coupled receptors.

Authors:  Miles Congreve; Christopher J Langmead; Jonathan S Mason; Fiona H Marshall
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.